The majority of cancer patients receive radiotherapy during the course of treatment,
delivered with curative intent for local tumor control or as part of a multimodality regimen …

Antigen cross‐priming of CD8+ T cells is a critical process necessary for the effective
expansion and activation of CD8+ T cells endowed with the ability to recognize and destroy …

Antigen cognate dendritic cell (DC)-T cell synaptic interactions drive activation of T cells and
instruct DCs. Upon receiving CD4+ T cell help, post-synaptic DCs (psDCs) are licensed to …

In contrast to conventional dendritic cells (cDCs) that are constantly exposed to microbial
signals at anatomical barriers, cDCs in systemic lymphoid organs are sheltered from …

Cytotoxic CD8+ T cells are potent killers of diseased cells, but their functional capacity is
often compromised in cancer. The quality of antitumor T cell immunity is determined during T …

Dendritic cells (DCs) are sentinel immune cells that form a critical bridge linking the innate
and adaptive immune systems. Extensive research addressing the cellular origin and …

CD4+ T cells can" help” or" license” conventional type 1 dendritic cells (cDC1s) to induce
CD8+ cytotoxic T lymphocyte (CTL) anticancer responses, as proven in mouse models. We …

Cross-priming was first recognized in the context of in vivo cytotoxic T lymphocyte (CTL)
responses generated against minor histocompatibility antigens induced by immunization …

Antiviral CD8+ T cell immunity depends on the integration of various contextual cues, but
how antigen-presenting cells (APCs) consolidate these signals for decoding by T cells …

Cancer immunotherapies, in particular checkpoint blockade immunotherapy (CBT), can
induce control of cancer growth, with a fraction of patients experiencing durable responses …